Inhibitory effects of flavonoids on molybdenum hydroxylases activity

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 2, 2010, Pages 133-152

  Rashidi, Mohammad Reza ^a   Nazemiyeh, Hossein ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Aldehyde oxidase; Flavonoids; Interaction; Molybdenum hydroxylase; Xanthine oxidase

Indexed keywords

ALDEHYDE OXIDASE; ALLOPURINOL; AURANTIIN; CATECHIN; CHALCONE; DAIDZEIN; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; FLAVANONE; FLAVONOID; GENISTEIN; HESPERETIN; HYDROGEN PEROXIDE; METALLOPROTEIN; POLYPHENOL; XANTHINE OXIDASE; XENOBIOTIC AGENT;

CATALYSIS; DIETARY INTAKE; DRUG ACTIVATION; DRUG DETOXIFICATION; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; IN VIVO STUDY; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ALDEHYDE OXIDASE; ANIMALS; DRUG INTERACTIONS; FLAVONOIDS; FOOD-DRUG INTERACTIONS; HUMANS; METALLOPROTEINS; MOLYBDENUM; OXIDATION-REDUCTION; PHYTOTHERAPY; PLANT EXTRACTS; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHINE OXIDASE; XENOBIOTICS;

EID: 76749109815     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903426164     Document Type: Review

References (117)

1. Harborne JB, Williams CA. Advances in Favonoid research since 1992. Phytochemistry 2000;55(6):481-504
2. Rice-Evans CA, Packer L. Flavonoids in Herbs. 2nd edition. Marcel Dekker, Inc. New York; 2003
3. Havsteen BH. The biochemistry and medical significance of the flavonoids. Pharmacol Ther 2002;96(2-3):67-202
4. Erlund I. Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res 2004;24:851-874
5. Moon YJ, Wang X, Morris ME. Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. Toxicology in Vitro 2006;20(2):187-210
6. Beedham C. Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. In: Ellis GP, West GB, editors, Progress in medicinal chemistry. Elsevier, Amsterdam, NewYork, Oxford:1987;24. p. 58-127
7. Beedham C. The role of non-P450 enzymes in drug oxidation. Pharm World Sci 1997;19(6):255-263
8. Strolin Benedetti M, Whomsley R, Baltes E. Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics. Expert Opin Drug Metab Toxicol 2006;2(6):895-921
9. Kitamura S, Sugihara K, Ohta S. Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet. 2006;21(2):83-98
10. Testa B, Krämer SD. The biochemistry of drug metabolism-an introduction: Part 2. Redox reactions and their enzymes. Chem Biodivers 2007;4(3):257-405 (Pubitemid 46937873)
11. Harborne JB, Grayer RJ. Flavonoids and insects. In: Harborne JB, editor, The flavonoids, advances in research since 1986. Chapman & Hall, London; 1994. p. 589-618
12. Alcaraz MJ, Jiménez MJ. Flavonoids as Anti-inflamatory agents. Fitoterapia 1988;59:25-38
13. Barnes S. Phytoestrogens and breast cancer. Baillieres Clin Endocrinol Metab 1998;12(4):559-579
14. Petersen J, Dwyer J. Flavonoids: dietary occurrence and biochemical activity. Nutr Res 1998;18(12):1995-2018
15. Craig WJ. Health-promoting properties of common herbs. Am J Clin Nutr 1999;70(3):491S-9S
16. Li-Weber M. New therapeutic aspects of flavones: The anticancer properties of Scutellaria and its main active constituents Woganin, Baicalein and Baicalin. Cancer Treat Rev 2009;35(1):57-68
17. Heim KE, Tagliaferro AR, Bobilya DJ. Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. J Nutr Biochem 2002;13(10):572-584
18. Cermak R. Effect of dietary flavonoids on pathways involved in drug metabolism. Expert Opin Drug Metab Toxicol 2008;4(1):17-35
19. Valerio LG, Kepa JK, Pickwell GV, Quattrochi LC. Induction of human NADPH:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin. Toxicol Lett 2001;119(1):49-57
20. Kuhnau J. The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rev Nutr Diet 1976;24:117-191
21. Peterson J, Dwyer J. Flavonoids: dietary occurrence and biochemical activity. Nutr Res 1998;18(12):1995-2018
22. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr 2000;130(8):2073S-85S
23. Stahl W, van den Berg H, Arthur J, et al. Bioavailability and metabolism. Mol Aspects Med 2002;23(1-3):39-100
24. Vanamala J, Reddivari L, Yoo KS, et al. Variation in the content of bioactive flavonoids in different brands of orange and grapefruit juices. J Food Compos Anal 2006;19(2,3):157-166
25. Yao LH, Jiang YM, ShiJ, et al. Flavonoids in food and their health benefits. Plant Foods Hum Nutr 2004;59(3):113-122
26. Erlund I, Meririnne E, Alfthan G, Aro A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J Nutr 2001;131(2):235-241
27. Erlund I, Silaste ML, Alfthan G, et al. Plasma concentrations of the flavonoids hesperetin, naringenin and quercetin in human subjects following their habitual diets, and diets high or low in fruit and vegetables. Eur J Clin Nutr 2002;56(9):891-898
28. Justesen U, Arrigoni E, Larsen BR, Amado R. Degradation of flavonoid glycosides and aglycones duting in vitro fermentation with human faecal flora. Food Sci Technol 2000;33(6):424-430
29. Aura A-M, O'Leary KA, Williamson G, et al. Quercetin derivatives are deconjugated and converted to hydroxyphenylacetic acids but not methylated by human fecal microflora in vitro. J Agric Food Chem 2002;50(6):1725-1730
30. Rechner AR, Smith MA, Kuhnle G, et al. Colonic metabolism of dietary polyphenols: influence of structure on microbial fermentation products. Free Radic Biol Med 2004;36(2):212-225
31. Walle T, Browning AM, Steed LL, et al. Flavonoid glycosides are hydrolyzed and thus activated on the oral cavity in humans. J Nutr 2005;135(1):48-52
32. Rice-Evans C. Serial Review: Flavonoids and Isoflavones (Phytoestrogens): absorption, metabolism, and bioactivity. Free Radic Biol Med 2004;36(7):827-828
33. Gee JM, DuPont MS, Day AJ, et al. Intestinal transport of quercetin glycosides in rats involves both deglycosylation and interaction with the hexose transport pathway. J Nutr 2000;130(11):2765-2771
34. Aura AM. Microbial metabolism of dietary phenolic compounds in the colon. Phytochem Rev 2008;7(3):407-429
35. Hill R, Massey V. In: Spiro TG, editor, Molybdenum enzymes. Wiley-Inter Science, New York; 1985. p. 443-518
36. Frausto de Silva, JJR, Williams RJP. In: The biological chemistry of the elements: the inorganic chemistry of life. Clarendon Press, Oxford; 1993. p. 411-435
37. Wajner M, Harkness RA. Distribution of xanthine dehydrogenase and oxidase activities in human and rabbit tissues. Biochim Biophys Acta 1989;991(1):79-84
38. Beedham C. Molybdenum hydroxylases. In: Ioannides C, editor, Enzyme systems that metabolise drugs and other xenobiotics. John Wiley & Sons Ltd.;2002. p. 147-187
39. Barber MJ, Coughlan MP, Rajagopalan KV, Siegel LM. Properties of the prosthetic groups of rabbit liver aldehyde oxidase: a comparison of molybdenum hydroxylase enzymes. Biochemistry 1982;21(15):3561-3568
40. Terao M, Kurosaki M, Demontis S, et al. Isolation and characterization of the human aldehyde oxidase gene: conservation of intron/exon boundaries with the xanthine oxidoreductase gene indicates a common origin. Biochem J 1998;332(Pt 2):383-393
41. Hille R. Molybdenum-containing hydroxylases. Arch Biochem Biophys 2005;433(1):107-116
42. Kundu TK, Hille R, Velayutham M, Zweier JL. Characterization of superoxide production from aldehyde oxidase: an important source of oxidants in biological tissues. Arch Biochem Biophys 2007;460(1):113-121
43. Adkins WK, Taylor AE. Role of xanthine oxidase and neutrophils in ischemia-reperfusion injury in rabbit lung. J Appl Physiol 1990;69:2012-2018
44. Johnson JL, Wadman SK. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors, The metabolic basis of inherited disease I. 6th edition, McGraw-Hill; 1989. p. 1463-1475
45. Brondino CD, Romão MJ, Moura I, Moura JJ. Molybdenum and tungsten enzymes: the xanthine oxidase family. Curr Opin Chem Biol 2006;10(2):109-114
46. Rajagopalan KV. Xanthine oxidase and aldehyde oxidase. In: Jakoby WB, editors, Enzymatic basis of detoxification. Academic Press, New York: 1980;Vol.1. p. 295-309
47. Testa B. The Metabolism of Drugs and other Xenobiotics: Biochemistry of redox reactions, Academic Press; 1995. p. 323-334
48. Johns DG. Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates. J Clin Invest 1967;46(9):1492-1505
49. Turner NA, Doyle WA, Ventom AM, Bray RC. Properties of rabbit liver aldehyde oxidase and the relationship of the enzyme to xanthine oxidase and dehydrogenase. Eur J Biochem 1995;232(2):646-657
50. Beedham C, Peet CF, Panoutsopoulos GI, et al. Role of aldehyde oxidase in biogenic amine metabolism. Prog Brain Res 1995;106:345-353
51. Rashidi MR, Smith JA, Clarke SE, Beedham C. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos 1997;25(7):805-813
52. Sugihara K, Katsuma Y, Kitamura S, et al. Cynomolgus monkey liver aldehyde oxidase: extremely high oxidase activity and an attempt at purification. Comp Biochem Physiol C Toxicol Pharmacol 2000;126(1):53-60
53. Tayama Y, Moriyasu A, Sugihara K, et al. Developmental changes of aldehyde oxidase in postnatal rat liver. Drug Metab. Pharmacokinet 2007;22(2):119-124
54. Critchley DJ, Rance DJ, Beedham C. Biotransformation of carbazeran in guinea pig: effect of hydralazine pretreatment. Xenobiotica 1994;24(1):37-47
55. Rodrigues AD. Comparison of levels of aldehyde oxidase with cytochrome P450 activities in human liver in vitro. Biochem Pharmacol 1994;48(1):197-200
56. Moriyasu A, Sugihara K, Nakatani K, et al. In vivo-in vitro relationship of methotrexate 7-hydroxylation by aldehyde oxidase in four different strain rats. Drug Metab Pharmacokinet 2006;21(6):485-491
57. Wurzinger K, Hartenstein R. Phylogeny and correlations of aldehyde oxidase, xanthine oxidase, xanthine dehydrogenase and peroxidase in animal tissues. Comp Biochem Physiol 1974;49(1B):171-185
58. Pirouzpanah S, Hanaee J, Razavieh SV, Rashidi MR. Inhibitory effects of flavonoids on aldehyde oxidase activity. J Enzyme Inhib Med Chem 2009;24(1):14-21
59. Kitamura S, Sugihara K, Nakatani K, et al. Variation of hepatic methotrexate 7-hydroxylase activity in animals and humans. IUBMB life 1999;48(6):607-611
60. Stanulović M, Chaykin S. Metabolic origins of the pyridones of N 1-methylnicotinamide in man and rat. Arch Biochem Biophys 1971;145(1):35-42
61. Nishino T, Tamura I. In: Harkness RA, Elion GB, Zöllner N, editors, Purine and pyrimidine metabolism in man. Plenum Press, New York: 1991;Vol. III, Part A. p. 327-333
62. Halliwell B, Cutteridge MC. Free radicals in biology and medicine. 3rd Edition, Oxford University Press, New York; 1999. p. 28-30
63. Harrison R. Physiological roles of xanthine oxidoreductase. Drug Metab Rev 2004;36(2):363-375
64. Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 2006;70(2):181-190
65. Aucamp J, Gaspar A, Hara Y, Apostolides Z. Inhibition of xanthine oxidase by catechins from tea (Camellia sinensis). Anticancer Res 1997;17(6D):4381-4385
66. Nagao A, Seki M, Kobayashi H. Inhibition of xanthine oxidase by flavonoids. Biosci Biotechnol Biochem 1999;63(10):1787-1790
67. Kong LD, Cai Y, Huang WW, et al. Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout. J Ethnopharmacol 2000;73(1-2):199-207
68. Van Hoorn DE, Nijveldt RJ, Van Leeuwen PA, et al. Accurate prediction of xanthine oxidase inhibition based on the structure of flavonoids. Eur J Pharmacol 2002;451(2):111-118
69. Lin CM, Chen CS, Chen CT, et al. Molecular modeling of flavonoids that inhibits xanthine oxidase. Biochem Biophys Res Commun 2002;294(1):167-172
70. Owen PL, Johns T. Xanthine oxidase inhibitory activity of northeastern North American plant remedies used for gout. J Ethnopharmacol 1999;64(2):149-160
71. Özyürek M, Bektaşóglu B, Güçlü K, Apak R. Measurement of xanthine oxidase inhibition activity of phenolics and flavonoids with a modified cupric reducing antioxidant capacity (CUPRAC) method. Analytica Chimica Acta 2009;636(1):42-50
72. Su JF, Guo CJ, Wei JY, et al. Protection against hepatic ischemia-reperfusion injury in rats by oral pretreatment with quercetin. Biomed Environ Sci 2003;16(1):1-8
73. Sarawek S, Feistel B, Pischel I, Butterweck V. Flavonoids of Cynara scolymus possess potent xanthinoxidase inhibitory activity in vitro but are devoid of hypouricemic effects in rats after oral application. Planta Med 2008;74(3):221-227
74. Mo SF, Zhou F, Lv YZ, et al. Hypouricemic action of selected flavonoids in mice: structure-activity relationships. Biol Pharm Bull 2007;30(8):1551-1556
75. Cos P, Ying L, Calomme M, et al. Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers. J Nat Prod 1998;61(1):71-76
76. Kong LD, Zhang Y, Pan X, et al. Inhibition of xanthine Oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchetia chinensis. CMLS, Cell Mol Life Sci 2000;57(3):500-505 (Pubitemid 30223575)
77. Theoduloz C, Franco L, Ferro E, Schmeda-Hirschmann G. Xanthine oxidase inhibitory activity of Paraguayan Myrtaceae. J Ethnopharmacol 1988;24(2-3):179-183
78. Schmeda-Hirschmann G, Zuiiiga J, Dutra-Behrens M, Rabermehl G. Xanthine oxidase inhibitory activity of flavonoids and tannins from Hexachlamys edulis (Myrtaceae). Phytother Res 1996;10(3):260-262
79. Boumerfeg S, Baghiani A, Messaoudi D, et al. Antioxidant properties and xanthine oxidase inhibitory effects of Tamus communis L. root extracts. Phytother Res 2009;23(2):283-288
80. Phuwapraisirisan P, Sowanthip P, Miles DH, Tip-pyang S. Reactive radical scavenging and xanthine oxidase inhibition of proanthocyanidins from Carallia brachiata. Phytother Res 2006;20(6):48-61
81. Graham HN. Green tea composition, consumption, and polyphenol chemistry. Prev Med 1992;21(3):334-350
82. Zhu JX, Wang Y, Kong LD, et al. Effects of Biota orientalis extract and its flavonoid constituents, quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver. J Ethnopharmacol 2004;93(1):133-140
83. Ioku K, Aoyama Y, Tokuno A, et al. Various cooking methods and the flavonoid content in onion. J Nutr Sci Vitaminol 2001;47(1):78-83
84. Walle T, Otake Y, Walle UK, Wilson FA. Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. J Nutr 2000;130(11):2658-2661
85. Haidari F, Rashidi MR, Eshraghian MR, et al. Hypouricemic and antioxidant activities of Allium cepa Lilliaceae and quercetin in normal and hyperuricemic rats. Saudi Med J. 2008;29(11):1573-1579
86. Haidari F, Mohammad Shahi M, Keshavarz SA, Rashidi MR. Inhibitory effects of tart cherry (prunus cerasus) juice on xanthine oxidoreductase activity and its hypouricemic and antioxidant effects on rats. Mal J Nutr 2009;15(1):53-64
87. Haidari F, Rashidi MR, Keshavarz SA, et al. Effects of onion on serum uric acid levels and hepatic xanthine dehydrogenase/ xanthine oxidase activities in hyperuricemic rats. Pak J Biol Sci 2008;11(14):1779-1784
88. Seeram NP, Bourquin LD, Nair MG. Degradation products of cyaniding glycosides from tart cherries and their bioactivities. J Agric Food Chem 2001;49(10):4924-4929
89. Seymour E, Lewis S, Urcuyo-Llanes D, Bolling S. The effect of tart cherry enriched diets on abdominal fat gene expression in rats. J Am Diet Assoc 2008;108(9):A14
90. Kanga SY, Seeram NP, Nair MG, Bourquin LD. Tart cherry anthocyanins inhibit tumor development in ApcMin mice and reduce proliferation of human colon cancer cells. Cancer Lett 2003;194(1):13-19
91. Kinoshita T, Lepp Z, Kawai Y, et al. An integrated database of lavonoids. Biofactors 2006;26(3):179-188
92. Costantino L, Rastelli G, Albasini A. Anthocyanidines as inhibitors of xanthine oxidase. Pharmazie 1995;50(8):573-574
93. Pirouzpanah S, Rashidi MR, Delazar A, et al. Inhibitory effects of Ruta graveolens L. extract on guinea pig liver aldehyde oxidase. Chem Pharm Bull 2006;54(1):9-13
94. Guarrera PM. Traditional antihelmintic, antiparasitic and repellent uses of plants in Central Italy. J Ethnopharmacol 1999;68(1-3):183-192
95. Skidmore-Roth L. Mosby's hand book of herbs and natural supplements, 1st edition, Mosby, New York; 2001. p. 741-744
96. Trovato A, Monforte MT, Forestieri AM, Pizzimenti F. In vitro anti-mycotic activity of some medicinal plants containing flavonoids. Boll Chim Farm 2000;139(5):225-227
97. Al-Okbi SY, El-Sayed EM, Ammar NM, et al. Effect of Ruta graveolens L. and Euphorbia peplus L. anti-inflammatory extracts on nutritional status of rats and the safety of their use. Indian J Exp Biol 2002;40(1):45-48
98. Atta AH, Alkofahi A. Anti-nociceptive and anti-inflammatory effects of some Jordanian medicinal plant extracts. J Ethnopharmacol 1998;60(2):117-124
99. Chen CC, Huang YL, Huang FI, et al. Water-soluble glycosides from Ruta graveolens. J Nat Prod 2001;64(7):990-992
100. Chiu KW, Fung AY. The cardiovascular effects of green beans (Phaseolus aureus), common rue (Ruta graveolens), and kelp (Laminaria japonica) in rats. Gen Pharmacol 1997;29(5):859-862
101. Alizadeh N. The effects of silybum marianum extracts and its flavonolignans on aldehyde oxidase and xanthine oxidase activity in rat, MSc Thesis, Islamic Azad University of Tehran; 2004
102. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998;93(2):139-143
103. Piscitelli SC, Formentini E, Burstein AH, et al. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 2002;22(5):551-555
104. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. Bio Drugs 2001;15(7):465-489
105. Johnson VJ, He Q, Osuchowski MF, Sharma RP. Physiological responses of a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits T-lymphocyte function at low doses but stimulates inflammatory processes at high doses. Planta Med 2003;69(1):44-49
106. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61(14):2035-2063
107. Luper S. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev 1998;3(6):410-421
108. Wu JW, Lin LC, Tsai TH. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol 2009;121(2):185-193
109. Sugihara K, Tayama Y, Shimomiya K, et al. Estimation of aldehyde oxidase activity in vivo from conversion ratio of N1-methylnicotinamide to pyridones, and intraspecies variation of the enzyme activity in rats. Drug Metab Dispos 2006;34(2):208-212
110. Jordan CG, Rashidi MR, Laljee H, et al. Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea-pig, rabbit and man. J Pharm Pharmacol 1999;51(4):411-418
111. Huh K, Shin US, Choi JW, Lee SI. Effect of sex hormones on lipid peroxidation in rat liver. Arch Pharmacol Res 1994;17(2):109-114
112. Lee DU, Shin US, Huh K. Structure-activity relationships of gagaminine and its derivatives on the inhibition of hepatic aldehyde oxidase activity and lipid peroxidation. Arch Pharmacol Res 1998;21(3):273-277
113. Beedham C, Peet CF, Panoutsopoulos GI, et al. Role of aldehyde oxidase in biogenic amine metabolism. Prog Brain Res 1995;106:345-353
114. Vorbach C, Harrison R, Capecchi MR. Xanthine oxidoreductase is central to the evolution and function of the innate immune system. Trends Immunol 2003;24(9):512-517
115. Obach RS. Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 2004;32(1):89-97
116. Obach RS, Huynh P, Allen MC, Beedham C. Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 2004;44(1):7-19
117. Rashidi MR, Malek A, Hanaee J, Hamidi A. In vitro study of interaction of some phenothiazines and purines with famciclovir metabolism catalyzed by guinea pig liver aldehyde oxidase. Pharmaceutic Sci 2004;1:87-96